Neumora Therapeutics Inc. (NMRA)
Neumora Therapeutics Inc. (NMRA) Stock Price, Analysis & Data
| Bid | 1.14 |
| Market Cap | 308.15M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -212.74M |
| Beta | 2.78 |
| EPS (ttm) | -1.23 |
| PE Ratio (ttm) | n/a |
| Forward PE | -2.45 |
| P/B (ttm) | 4.23 |
| P/S (ttm) | n/a |
| Earnings Date | Nov 5, 2026 |
| Ask | 1.9 |
| Volume | 781,375 |
| Avg. Volume (20D) | 1,959,237 |
| Open | 1.50 |
| Previous Close | 1.52 |
| Day's Range | 1.48 - 1.65 |
| 52-Week Range | 0.83 - 3.65 |
| Analyst | Buy |
| Price Target | 5 (204.88%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About NMRA
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases in the United States. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in Phase 1b...
Financial Performance
In 2025, Neumora Therapeutics's revenue was 0, an increase of undefined% compared to the previous year's 0. Earnings were -236.93M, a decrease of -2.81%.
Financial StatementsAnalyst Forecast
According to 8 analyst ratings, the average rating for NMRA stock is "Buy". The 12-month stock price forecast is 5, which is upside of 204.88% from the latest price.
Stock ForecastsEarnings Surprise
Analysts project revenue of ... Upgrade
